PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “TESTICULAR NEOPLASMS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 253 records · Page 14Linked to original sources
PubMed1997

Fifteen-year experience of testicular neoplasm in a regional centre.

BACKGROUND: During a 15-year period from 1980 to 1995, 63 patients from the Geelong region of Victoria presented with germ cell neoplasm. METHODS: In this retrospective review performed by studying hospital records, treating specialists' notes and by telephone interviews, 61 of 63 patients were identified. RESULTS: A tumour incidence of four cases per 100,000 male population per year with an overall cancer-specific survival of 95% is demonstrated. Follow-up ranged from 18 months to 15 years. The incidence of seminoma was 30%; patients with seminoma presented at a later stage than those with non-seminoma. CONCLUSIONS: The present study demonstrates the increasing incidence of testicular tumour in the Geelong region, and the excellent prognosis of this disease with management outside of the tertiary referral centre.

Adolescent↗
PubMed2004

[The sperm quality in young patients before cancer therapy].

In the last years increasing incidence of malignant diseases in young men is observed. Sperm cryopreservation before cancer therapy gives the opportunity for these men to have a child in the future, but it is not know whether pretreatment sperm quality is sufficient to preserve fertility potential after thawing. The aim of this study was to compare the semen parameters (volume, total count, concentration, motility, morphology) in young cancer patients before treatment with healthy men, and examining the differences in sperm quality among patients group. Semen specimens were obtained from 81 patients with different neoplasms (testicular cancer n = 65, others n = 16 (Hodgkin's disease n = 11, lymphoma n = 3, Ewing's sarcoma n = 1, osteosarcoma n = l1). Control group consisted of 43 healthy males at similar age that came to our division as potential sperm donors. The total sperm count, concentration per ml, motility (grade A, B and C) and morphology were significantly lower in the cancer patients compared with normal men (p < 0.05), but still adequate for the future assisted reproductive technologies. Patients with testicular neoplasms had only significantly lower total sperm count and concentration in comparison with other cancer patients (p < 0.05). Our results indicate that routine sperm banking should be offered for men before radio/chemotherapy to preserve future fertility.

Adult↗
PubMed2005

Testicular natural killer T-cell lymphoma.

Primary testicular lymphomas account for less than 5% of all testicular neoplasms. Testicular natural killer (NK)/T-cell lymphomas are exceptional and have a very poor prognosis. We report the case of a 30-year-old French Caucasian man with testicular NK/T-cell lymphoma of the following immunophenotype: CD2+, CD3epsilon+ and CD56+. Despite intensive chemotherapy, the disease progressed rapidly, with death occurring 2 months after diagnosis.

Adult↗
PubMed1996

Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms.

PURPOSE: Testicular intraepithelial neoplasia ([TIN], so-called carcinoma in situ of the testis) is hypothesized to be the precursor of testicular germ cell neoplasms. According to previous studies, it can be detected by testicular biopsy. Since patients with a unilateral testicular tumor are at high risk of a second testicular tumor, it seemed feasible to examine the prevalence of contralateral TIN in patients with testicular germ cell cancer and correlate it with the known prevalence of bilateral testicular tumors. The aim was to provide more evidence for the role of TIN as the preinvasive stage of testicular cancer. PATIENTS AND METHODS: Nineteen hundred fifty-four consecutive patients with a unilateral testicular germ cell tumor underwent contralateral biopsy. All specimens were examined immunohistologically. RESULTS: TIN was observed in 4.9% (95% confidence interval [CI], 3.95% to 5.91%). Testicular atrophy and a history of undescended testis were more frequently observed in patients with contralateral TIN, but only atrophy was shown to be independently associated by multivariate analysis. Patients with testicular atrophy have a 4.3-fold increased risk of having contralateral TIN. Sixty-four percent of TIN cases were found in normal testes. Patients with TIN were significantly younger than those without (P < .0017). Three patients developed a second testicular tumor despite a negative biopsy for TIN. CONCLUSION: The prevalence of contralateral TIN corresponds well to the known prevalence of bilateral testicular tumors. Testicular atrophy is a strong indicator for the presence of TIN, but approximately 60% of TIN cases occur without atrophy. The present data are in accordance with the theory that TIN is an early step in the histogenesis of testicular germ cell neoplasms.

Adolescent↗
PubMed1986

Low-attenuation thoracic metastases in testicular malignancy.

Low-density abdominal and pelvic lymph nodes are seen in nearly half of patients with testicular cancers. Thoracic low-attenuation metastases are much less common. Three cases of low-density metastases to lung parenchyma and mediastinal nodes are presented. In a man of appropriate age, a low-attenuation pulmonary or mediastinal mass should prompt a search for a primary testicular neoplasm.

Adult↗
PubMed2003

Malignant Sertoli cell tumor in the retained abdominal testis of a unilaterally cryptorchid horse.

A 13-year-old Morgan gelding was evaluated because of a mass in the caudal region of the abdomen. The horse had been presumed to be a gelding, but necropsy findings revealed a retained testis in the right retroperitoneal space. Histologically, the retained testis contained neoplastic cells; metastases were identified in the liver, spleen, lungs, and sublumbar lymph nodes. Immunohistochemical examination of the testis and metastatic tissues confirmed the diagnosis of malignant Sertoli cell tumor. Testicular neoplasms are infrequently reported in stallions. Seminomas are most commonly reported, whereas Sertoli cell tumors are considered to be rare. Typical biological behavior of Sertoli cell tumors in horses is unknown. To the authors' knowledge, there have been 2 reports of Sertoli cell tumors in horses; the tumors developed in descended testes, and 1 tumor was malignant.

Animals↗
PubMed1978

Phase I trial of vindesine in patients with advanced cancer.

A phase I evaluation of vindesine was carried out in 69 adult patient with advanced malignancies. Two escalating dose schedules were explored: (a) a single dose every 7--14 days, and (b) daily injections X 5--10 days as tolerated. The main toxic effects were myelosuppression, alopecia, paresthesia, asthenia, myalgia, and hyporeflexia. Antitumor activity was seen during this phase I study in patients with leukemia, lymphoma, and testicular neoplasms. Disease oriented phase II trials of 3--4 mg/m2 every 7--14 days or 1.3--2.0 mg/m2/day X 5--7 days every 3 weeks would be appropriate.

Adult↗
PubMed1986

Metastatic tumours of the testes.

Metastatic tumours of the testes are uncommon, making up little more than 2% of all testicular neoplasms. The most frequent primary sites are the lung and prostate. Only rarely do these lesions present clinically either as the first sign of malignant disease or as a complicating factor during the course of known disease. The authors present two cases illustrating both of these occurrences. The first, a man with carcinoma of the common bile duct, initially had a mass in the testicle and the second, a patient with carcinoma of the prostate, had his clinical course complicated by a symptomatic metastasis to the right testis. The authors also reviewed their local autopsy experience and identified 16 more cases. Metastases were grossly visible in 38% (6 of 16). The most frequent primary sites were lung (four cases), stomach (four) and prostate (three). Routes of spread as well as possible explanations for the low incidence are discussed.

Adenocarcinoma↗
PubMed1996

Prolonged expression of the c-kit receptor in germ cells of intersex fetal testes.

Stem cell factor (SCF) and its receptor Kit encoded by the c-kit proto-oncogene are crucial for the development and migration of primordial germ cells in rodents. The expression of Kit has been examined immunohistochemically in gonads obtained from five specimens of fetal tissues with intersex conditions which included 45,X/46,XY mosaicism; androgen insensitivity syndrome; and 46,XY/iso(p)Y mosaicism. Individuals with such disorders of sexual differentiation and Y-chromosome material carry a very high risk of developing testicular neoplasms. Fetal testicular germ cells of the intersex subjects expressed Kit at a later developmental age than controls, in which no Kit protein was detectable beyond the 15th week of gestation. This finding may indicate a disturbance of the chronology of germ cell development, or it may suggest a change of the regulation of c-kit expression in subjects with disorders of gonadal development.

Disorders of Sex Development↗
PubMed1998

[Primary retroperitoneal extragonadal germ cell tumor].

A case is presented of a primary extragonadal retroperitoneal germ cell tumor (seminoma) in a 51-year-old male. The ultimate diagnosis was only achieved after curative surgical resection of the tumor. There was no demonstrable testicular neoplasm.

Germinoma↗
PubMed1998

[Testicular intraepithelial neoplasms (TIN). An indication for radiotherapy?].

BACKGROUND: Testicular intraepithelial neoplasia (TIN), synonymous for carcinoma in situ of the testis, is a rarely observed preinvasive neoplasia located within the germinative epithelium. According to the current knowledge of the biology of TIN, it is the common precursor of all testicular germ cell neoplasms except spermatocytic seminoma. MATERIAL AND METHODS: This report provides a review of histopathology, epidemiology and diagnostic procedures for TIN and discusses the therapeutic options with particular respect to radiooncological aspects. RESULTS: TIN has a 70% rate of progression to invasive cancer within 7 years. Depending on the individual therapeutic setting surgery, chemotherapy and radiotherapy are alternative treatment modalities. In case of TIN in a single testis or bilateral TIN, local radiotherapy is the standard procedure. With 20 Gy recommended as standard dose in Germany, radiotherapy yields safe eradication of TIN. However, some of the patients show significantly reduced synthesis of testicular androgens. With respect to sporadic reports in the literature, total doses well below 20 Gy might be equally efficient to treat TIN safely. Yet, up to date neither the minimum dose for efficient treatment nor the toxicity profile after consecutive chemo-radiotherapy has been established. CONCLUSIONS: The currently recommended standard dose of 20 Gy in Germany is probably in excess of the minimum dose needed for safe eradication of TIN. Thus, new radiooncological strategies should aim at reducing the total dose of treatment in order to minimize late side effects while maintaining the high efficacy of radiotherapy. This topic is under investigation in a multicenter clinical trial.

Antineoplastic Agents↗
PubMed1991

Malignant potential of the cryptorchid testis.

A follow-up study of 224 male patients from Rochester, Minnesota, diagnosed with cryptorchidism during the period from 1935 through 1974 was conducted to assess the frequency of subsequent testicular neoplasms. Age-specific rates for testicular neoplasm in this community were used to estimate an expected number for comparison with that observed. Two malignant testicular neoplasms have occurred in this cohort; thus, the standardized morbidity ratio was 11.4 (95% confidence interval, 1.4 to 41.1). Of the 158 patients born in the community, 11% were known to have birth weights of less than 2,500 g, approximately twice the expected occurrence. Increased risks were also noted for inguinal hernia, hypospadias, Down's syndrome, cleft lip or palate (or both), clubfoot, and congenital heart disease, for which the standardized morbidity ratios were 3.6, 4.7, 17.8, 11.3, 11.7, and 2.7, respectively. The increased risk for malignant neoplasms observed in this cohort of patients with cryptorchidism is consistent with that found in earlier studies.

Abnormalities, Multiple↗
PubMed2004

Testicular microlithiasis and its relation to testicular cancer on ultrasound findings of symptomatic men.

PURPOSE: We reviewed testicular microlithiasis (TM) on scrotal ultrasound in relation to the incidence of testicular neoplasm in males 17 to 45 years old with scrotal symptoms. MATERIALS AND METHODS: We reviewed the radiographic and medical records of males age 4 weeks to 84 years with symptomatic complaint of scrotal pain or swelling between September 1998 and April 2002. Subgroup analysis was performed on 160 male patients between 17 and 45 years old since they were at higher risk for testicular carcinoma. RESULTS: TM was found in 12 patients (8%) and concomitant testicular neoplasm was found in 4 (33%) symptomatic individuals age 17 to 45. In the 148 (93%) patients without testicular microlithiasis, concomitant testicular neoplasm was found in 2 individuals (2%). Statistical analysis revealed a relative risk of testicular neoplasm in the presence of TM to be 36.5 (CI 4.2-429.6) in our symptomatic population. Sensitivity and specificity were 0.67 and 0.95, respectively. CONCLUSIONS: Symptomatic patients with TM exhibited an incidence of testicular neoplasm greater than that of the general population. An algorithm for the surveillance of patients with TM should be developed. The fact that our patient population was symptomatic at referral preselected toward a higher incidence of TM and testicular neoplasm compared to accepted incidence in the general population. Further investigation will require a multicenter trial to generate an adequate patient pool due to the low incidence of TM and testicular malignancy.

Adolescent↗
PubMedDate not supplied

[Epidemiological analysis of testicular malignant neoplasm incidence and mortality in Poland 1963-1986].

Epidemiological analysis of both morbidity and mortality rates for testicular cancer in Poland between 1963 and 1986 was carried out. A particular attention was drawn to the period between 1981 and 1986, when a program of combined chemotherapy and surgery was introduced in Poland. The study aimed at analysing an effect of this combined treatment on mortality rate for testicular cancer. Between 1963 and 1986, a constant increase in morbidity for the testicular cancer was noted. Mortality rate increased between 1963 and 1983. This trend was inhibited between 1984 and 1986. "Splitting" of the morbidity and mortality curves was observed between 1984 and 1986. A decrease in mortality rate was noted at the constant morbidity for testicular tumors. It was particularly clear in younger age groups (15-39 years), as well as older age groups (60-64 years and over 75 years). A decrease in mortality rate for testicular tumors within 1984-1986 may be attributed to the introduction of combined treatment in Poland.

Adolescent↗